295,525 Shares in CVS Health Co. (NYSE:CVS) Bought by Cantor Fitzgerald Investment Advisors L.P.

Cantor Fitzgerald Investment Advisors L.P. acquired a new position in CVS Health Co. (NYSE:CVS) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 295,525 shares of the pharmacy operator’s stock, valued at approximately $23,335,000. CVS Health makes up approximately 1.8% of Cantor Fitzgerald Investment Advisors L.P.’s holdings, making the stock its 10th largest position.

Other large investors have also recently made changes to their positions in the company. Atticus Wealth Management LLC lifted its stake in shares of CVS Health by 149.0% in the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 219 shares during the last quarter. USA Financial Formulas lifted its position in CVS Health by 573.2% in the fourth quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 321 shares during the last quarter. Cornerstone Planning Group LLC increased its position in CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after acquiring an additional 243 shares during the last quarter. ZRC Wealth Management LLC raised its stake in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Finally, Northwest Financial Advisors bought a new position in CVS Health during the 4th quarter valued at about $42,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Down 0.2 %

Shares of CVS stock traded down $0.11 during trading hours on Friday, reaching $55.54. 11,725,739 shares of the company’s stock were exchanged, compared to its average volume of 17,230,286. CVS Health Co. has a fifty-two week low of $53.70 and a fifty-two week high of $83.25. The stock’s 50 day moving average is $67.13 and its 200-day moving average is $71.94. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.78. The company has a market cap of $69.72 billion, a price-to-earnings ratio of 9.76, a P/E/G ratio of 0.53 and a beta of 0.56.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The business had revenue of $88.44 billion during the quarter, compared to analysts’ expectations of $89.33 billion. During the same quarter last year, the business posted $2.20 earnings per share. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. Analysts predict that CVS Health Co. will post 7.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd were paid a dividend of $0.665 per share. The ex-dividend date was Friday, April 19th. This represents a $2.66 annualized dividend and a dividend yield of 4.79%. CVS Health’s payout ratio is currently 46.75%.

Insider Buying and Selling

In other news, Director Edward J. Ludwig purchased 1,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were acquired at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the purchase, the director now owns 21,630 shares in the company, valued at $1,165,424.40. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.24% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on CVS. The Goldman Sachs Group dropped their target price on CVS Health from $85.00 to $74.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Bank of America decreased their target price on CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. TD Cowen cut shares of CVS Health from a “buy” rating to a “hold” rating and cut their price target for the stock from $99.00 to $59.00 in a report on Tuesday, May 7th. Royal Bank of Canada decreased their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a report on Thursday, February 8th. Finally, StockNews.com downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Thursday, February 15th. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $76.75.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.